Advertisement

Topics

Latest Enbrel NewsRSS

10:51 EDT 19th March 2019 | BioPortfolio

Amgen's top-selling Enbrel in balance as key court ruling nears

A decision could come as soon as this month in a court case pitting Amgen against Sandoz, which owns the only U.S. approval of an Enbrel biosimilar.

Human medicines European public assessment report (EPAR): Lifmior, etanercept, Arthritis, Psoriatic,Spondylitis, Ankylosing,Psoriasis, Date of authorisation: 13/02/2017, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Lifmior, etanercept, Arthritis, Psoriatic,Spondylitis, Ankylosing,Psoriasis, Date of authorisation: 13/02/2017, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Enbrel, etanercept, Spondylitis, Ankylosing,Arthritis, Juvenile Rheumatoid,Arthritis, Psoriatic,Psoriasis,Arthritis, Rheumatoid, Date of authorisation: 02/02/2000, Revision: 58, Status: Authorised

Human medicines European public assessment report (EPAR): Enbrel, etanercept, Spondylitis, Ankylosing,Arthritis, Juvenile Rheumatoid,Arthritis, Psoriatic,Psoriasis,Arthritis, Rheumatoid, Date of authorisation: 02/02/2000, Revision: 58, Status: Authorised

Mandatory and non-mandatory switching for biosimilars

Glintborg and co-authors responded to the comments made by Marc Scherlinger and Thierry Schaeverbeke on their paper ‘To switch or not to switch’, which reported the results of biosimilar etanercept switching in Denmark [1].

Questions over DANBIO relevance for non-medical switching

Italian rheumatologists Fabrizio Cantini and Maurizio Benucci commented on the paper from Glintborg and co-authors ‘To switch or not to switch’, which reported the results of biosimilar etanercept switching in Denmark [1].

Sandoz makes biological deal in China

Sandoz has made a deal with for copy biological in China in December 2018, and received approval of an extra indication for its biosimilar etanercept in January 2019.

LabCorp Strengthens Leadership Position in Precision Medicine with Expansion of Therapeutic Drug Monitoring Portfolio

LabCorp’s DoseASSURE® Portfolio Provides Most Expansive Biologics TDM Menu Combined with Expert Guidance LabCorp® (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, today announced a new assay in its therapeutic drug monitoring (TDM) DoseASSURE® portfolio. The new Certolizumab Concentrat...

Enbrel – Drug Insight, 2019-2021 with Historical & Forecasted Sales Analysis – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Enbrel – Drug Insight, 2019” report has been added to ResearchAndMarkets.com’s offering. Enbrel Drug Insight, 2019 highlights the drug marketed details and the Global API Manufacturers details across the globe along with the location. The report covers the … Continue reading →

Here comes the second wave of drug price hikes of 2019 $AMGN Enbrel +6% Kyprolis +3% Blincyto +3% Prolia +3% Xgeva +3% $BHC Xifaxan +7.9% Wellbutrin +6% Relistor +6% Uceris +6% Apriso +6% Lotemax +6% Elidel +6% $CLVS Rubraca +8% $EXEL Cabometyx +5% Co

Here comes the second wave of drug price hikes of 2019 $AMGN Enbrel +6% Kyprolis +3% Blincyto +3% Prolia +3% Xgeva +3% $BHC Xifaxan +7.9% Wellbutrin +6% Relistor +6% Uceris +6% Apriso +6% Lotemax +6% Elidel +6% $CLVS Rubraca +8% $EXEL Cabomet

Pfizer, Novartis, Amgen add to 2019 drug price hikes

Prices were increased on major products including Novartis' Cosentyx, Pfizer's Xeljanz and Amgen's Enbrel.

Biosimilars - to switch or not to switch

Authors Marc Scherlinger and Thierry Schaeverbeke commented on the paper from Glintborg and co-authors ‘To switch or not to switch’ ,which reported the results of biosimilar etanercept switching in Denmark[1].

KOL Perspectives: Perceptions of Lupus Pipeline Therapy Data Presented at EULAR 2018 [Report Updated: 18092018] Prices from USD $2500

KOL Perspectives: Perceptions of Lupus Pipeline Therapy Data Presented at EULAR 2018SummaryThis KOL Insight briefing focuses on KOLs views of Pipeline Therapy Data Presented at EULAR 2018.Questions topics Opinion on abatacept failing to achieve its primary endpoint in its Phase III LN trial Views on the Phase III safety data for abatacept in LN Expectations regarding abatacept's future developme...

Positive results for adalimumab and etanercept biosimilars from Sandoz

On 23 October 2018, Sandoz, the generics division of Novartis, presented positive phase III data for its adalimumab and etanercept biosimilars [1, 2].

Human medicines European public assessment report (EPAR): Enbrel, etanercept, Spondylitis, Ankylosing,Arthritis, Juvenile Rheumatoid,Arthritis, Psoriatic,Psoriasis,Arthritis, Rheumatoid, Date of authorisation: 02/02/2000, Revision: 57, Status: Authorised

Human medicines European public assessment report (EPAR): Enbrel, etanercept, Spondylitis, Ankylosing,Arthritis, Juvenile Rheumatoid,Arthritis, Psoriatic,Psoriasis,Arthritis, Rheumatoid, Date of authorisation: 02/02/2000, Revision: 57, Status: Authorised

Changing markets: A look at rheumatoid arthritis

Medicines like Humira and Enbrel remain top treatments for the inflammatory condition. Drugmakers, though, still see opportunity for growth.

Human medicines European public assessment report (EPAR): Benepali, etanercept, Arthritis, Psoriatic,Arthritis, Rheumatoid,Psoriasis, Date of authorisation: 13/01/2016, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Benepali, etanercept, Arthritis, Psoriatic,Arthritis, Rheumatoid,Psoriasis, Date of authorisation: 13/01/2016, Revision: 7, Status: Authorised

KOL Perspectives: Perceptions of Lupus Pipeline Therapy Data Presented at EULAR 2018 [Report Updated: 18092018] Prices from USD $2125

KOL Perspectives: Perceptions of Lupus Pipeline Therapy Data Presented at EULAR 2018SummaryThis KOL Insight briefing focuses on KOLs views of Pipeline Therapy Data Presented at EULAR 2018.Questions topics Opinion on abatacept failing to achieve its primary endpoint in its Phase III LN trial Views on the Phase III safety data for abatacept in LN Expectations regarding abatacept's future developme...

Something to think about: The patient in this story transcended her illness not because of two powerful drugs -- Humira and Enbrel -- but in spite of them. https://www.statnews.com/2018/11/14/humira-abbvie-amgen-enbrel-price-hikes-biosimilars/ … via

Something to think about: The patient in this story transcended her illness not because of two powerful drugs -- Humira and Enbrel -- but in spite of them. https://www.statnews.com/2018/11/14/humira-abbvie-amgen-enbrel-price-hikes-biosimilars/ … via @statnews

Humira and Enbrel are rock star drugs. But the large, lockstep price hikes by @abbvie and @Amgen are undermining care, creating perverse incentives, and increasing overall costs. My latest investigation: https://bit.ly/2RWjwwV 

Humira and Enbrel are rock star drugs. But the large, lockstep price hikes by @abbvie and @Amgen are undermining care, creating perverse incentives, and increasing overall costs. My latest investigation: https://bit.ly/2RWjwwV 

Switching to etanercept biosimilar SB4 safe and effective in a hospital setting

Authors of a study carried out at a UK hospital found switching to etanercept biosimilar SB4 to be safe and effective [1].

$AMGN 1st to launches biosimilar Humira In Europe https://www.prnewswire.com/news-releases/amgen-launches-amgevita-biosimilar-adalimumab-in-markets-across-europe-300731419.html … EU #biosimilars adoption been amazing: Remicade/Enbrel/Rituxan all see

$AMGN 1st to launches biosimilar Humira In Europe https://www.prnewswire.com/news-releases/amgen-launches-amgevita-biosimilar-adalimumab-in-markets-across-europe-300731419.html … EU #biosimilars adoption been amazing: Remicade/Enbrel/Rituxan all see >90% biosim uptake in some countries Meanwhile in US, Remic

PIXACORE WINS MM&M 2018 Mid-Size Healthcare Agency of the Year!

All told, Pixacore landed 14 new accounts last year, including two new AOR assignments from existing client Bayer. More than 80% of the growth was organic. Wins from new clients included project work on Amgen’s Enbrel. New York, New York (PRWEB) October 15, 2018 After an exciting night at the MM&M awards ceremony, PIXACORE is thrilled to announce the win of the 2018 MM&M award for Mid-S...

Australia’s Government Advances a New Era in Stroke Treatment

This week the Australian government has taken a noteworthy step forward, announcing it will invest funds to commence study of a new kind of drug treatment, perispinal etanercept (PSE), for chronic stroke dysfunction in Australia. Source: Institute of Neurological Recovery. BOCA RATON, Fla. (PRWEB) October 11, 2018 This week the Australian government has taken a noteworthy step forward, announcing...

Very interesting chart from Leerink showing price hikes contributed 61% of the growth in US sales for top 45 drugs over the past 3 years So what happens when this driver goes away... $AMGN Enbrel >100% $BIIB Tysabri >100% $BIIB Avonex >100% $CELG Revlimi

Very interesting chart from Leerink showing price hikes contributed 61% of the growth in US sales for top 45 drugs over the past 3 years So what happens when this driver goes away... $AMGN Enbrel >100% $BIIB Tysabri >100% $BIIB Avonex >100%

Kaleidoscope Innovation Hires New Director of Insights and Human Factors to Promote the Value and Knowledge of User-Centered Design

With over 30 years of developing powerful and user-centered design, new director brings human-focused insight and passion to this critical leadership role. CINCINNATI (PRWEB) October 04, 2018 Kaleidoscope Innovation, a product development firm that provides services ranging from insights, design and development, has hired Valerie Fenster as the new Director of Insights and Human Factors. Valerie ...

Advertisement
Quick Search
Advertisement
Advertisement

 

review and buy Enbrel market research data and corporate reports here